RedHill Biopharma (NASDAQ:RDHL) Earns Hold Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of RedHill Biopharma (NASDAQ:RDHL) in a research report issued on Wednesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

RedHill Biopharma Stock Down 0.9 %

Shares of NASDAQ RDHL opened at $6.58 on Wednesday. The business has a 50-day simple moving average of $7.27 and a two-hundred day simple moving average of $76.46. RedHill Biopharma has a 52 week low of $6.00 and a 52 week high of $34.00. The company has a market cap of $8.43 million, a P/E ratio of -0.66 and a beta of 3.69.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in RedHill Biopharma stock. GAMMA Investing LLC acquired a new position in RedHill Biopharma Ltd. (NASDAQ:RDHL) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 5,089 shares of the biotechnology company’s stock, valued at approximately $32,000. GAMMA Investing LLC owned approximately 0.40% of RedHill Biopharma as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 7.20% of the company’s stock.

About RedHill Biopharma

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.